Investigational drug · Phase 2
TCP-25
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "TCP-25"
First trial start
2026
Jan 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TCP-25", any sponsor or status.
Conditions studied
As listed on its trial records.
- Epidermolysis Bullosa (EB)
- Dystrophic Epidermolysis Bullosa
- Junctional Epidermolysis Bullosa
Approved drugs for the same conditions: Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "TCP-25" as an intervention, largest first.
Xinnate ABIndustry
NCT05378997 · 35 participants · Start Apr 7, 2022 · Primary completion Mar 16, 2024
Drug: TCP-25 gel 0.86 mg/ml or placebo gel; TCP-25 gel 2.9 mg/ml or placebo gel and 1 more · For: Blister; Wound of Skin; Epidermolysis Bullosa and 1 more
Sites: Lund, Sweden
Xinnate ABIndustry
NCT06594393 · 32 participants (planned) · Start Jan 30, 2026 · Primary completion Jun 30, 2027
Drug: TCP-25 gel; Vehicle (placebo) · For: Epidermolysis Bullosa (EB); Dystrophic Epidermolysis Bullosa; Junctional Epidermolysis Bullosa
Sites: Cincinnati, Ohio; Paris, France; Athens, Greece · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A First-In-Human Randomized Controlled Phase 1 Study Assessing the Safety and Tolerability of Topical TCP-25 Gel in Epidermal Suction Blister Wounds.
Wallblom K, Lundgren S, Petruk G, et al. · Clin Transl Sci 2026
- Results of a non-randomized, open-label phase I study evaluating the novel immunomodulatory peptide TCP-25 for treatment of dystrophic epidermolysis bullosa.
Wallblom K, Holmgren K, Lundgren S, et al. · Orphanet J Rare Dis 2025
- Functionalized peptide hydrogels: enabling dynamic stage-adaptive modulation for wound healing.
Ma XK, Peng Q, Miao GH, et al. · Front Cell Dev Biol 2025
- A murine pressure ulcer model for evaluating persistence and treatment of Staphylococcus aureus infection.
Tavecchio M, Fanni S, Wu X, et al. · Front Med (Lausanne) 2025
- Bioactive Suture with Added Innate Defense Functionality for the Reduction of Bacterial Infection and Inflammation.
Puthia M, Petrlova J, Petruk G, et al. · Adv Healthc Mater 2023
- Study protocol for a phase 1, randomised, double-blind, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of ascending topical doses of TCP-25 applied to epidermal suction blister wounds in healthy male and female volunteers.
Lundgren S, Wallblom K, Fisher J, et al. · BMJ Open 2023
Also in development for Epidermolysis Bullosa (EB)
- SD-101 DermalPhase 32 trials
Paradigm Therapeutics · Epidermolysis Bullosa (EB)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.